European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Aquipta, atogepant, Date of authorisation: 11/08/2023, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 25 August 2026 - 14:00

Human medicines European public assessment report (EPAR): Aquipta, atogepant, Date of authorisation: 11/08/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Verzenios, abemaciclib, Date of authorisation: 26/09/2018, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 25 August 2026 - 13:42

Human medicines European public assessment report (EPAR): Verzenios, abemaciclib, Date of authorisation: 26/09/2018, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Liraglutide STADA, liraglutide, Date of authorisation: 15/07/2026, Status: Authorised

Submitted by Anonymous (not verified) on 25 August 2026 - 13:40

Human medicines European public assessment report (EPAR): Liraglutide STADA, liraglutide, Date of authorisation: 15/07/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Rezurock, belumosudil, Date of authorisation: 24/03/2026, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 25 August 2026 - 13:31

Human medicines European public assessment report (EPAR): Rezurock, belumosudil, Date of authorisation: 24/03/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Svariya (previously Rivaroxaban Koanaa), rivaroxaban, Date of authorisation: 21/11/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 25 August 2026 - 13:22

Human medicines European public assessment report (EPAR): Svariya (previously Rivaroxaban Koanaa), rivaroxaban, Date of authorisation: 21/11/2025, Revision: 1, Status: Authorised

Webinar on the use of platform approaches in the non-clinical and clinical domains, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 March 2026, 09:25 (CET) to 2 March 2026, 12:30 (CET)

Submitted by Anonymous (not verified) on 25 August 2026 - 10:23

Webinar on the use of platform approaches in the non-clinical and clinical domains, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 March 2026, 09:25 (CET) to 2 March 2026, 12:30 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness